Course: Specialization in Methodology and Ethics of Oncological Clinical Trials (European Institute of Oncology): Difference between revisions
m (Update categories.) |
m (Update categories.) |
||
| Line 95: | Line 95: | ||
<span style="display:none">Spleen</span> | <span style="display:none">Spleen</span> | ||
<span style="display:none">Leukemia</span> | <span style="display:none">Leukemia</span> | ||
<span style="display:none">isTraining</span> | |||
<span style="display:none">hasCancerType::C00-C97: All cancer types</span> | <span style="display:none">hasCancerType::C00-C97: All cancer types</span> | ||
<span style="display:none">hasCancerType::C00-D48: All neoplasms</span> | <span style="display:none">hasCancerType::C00-D48: All neoplasms</span> | ||
<span style="display:none">hasCancerType::C00-C14: Mouth/throat cancers</span> | <span style="display:none">hasCancerType::C00-C14: Mouth/throat cancers</span> | ||
| Line 113: | Line 113: | ||
<span style="display:none">hasCancerType::C81-C96: Cancers of the blood and immune system</span> | <span style="display:none">hasCancerType::C81-C96: Cancers of the blood and immune system</span> | ||
<span style="display:none">hasCancerType::C97-C97: Cancers in multiple locations from the start</span> | <span style="display:none">hasCancerType::C97-C97: Cancers in multiple locations from the start</span> | ||
Revision as of 18:56, 10 December 2025
Go back to European Institute of Oncology page
Primary purpose: To equip professionals and researchers with methodological, regulatory, and bioethical knowledge necessary to conduct clinical trials, particularly in oncology.
Target audience: Oncologists or specializing in oncology, investigators, research nurses, healthcare professionals, data managers, monitors, biologists and biotechnologists researchers, bioinformatics and biostatisticians, clinical and research psychologists, bioethicists, biolaw experts, medical examiners, medical humanities researchers.
Cancer areas of interest: C00-C97: All cancer types. Click here to learn more.
Information: Click here to access.
